Add BrightSurf on Google Email

Study reveals financial hardship for cancer survivors due to high-cost immunotherapies, especially among blood cancer patients

A study found that blood cancer survivors are more likely to face financial hardship and take fewer medications due to high-cost immunotherapy treatments. Financial strain affects both Medicare-insured and uninsured patients, highlighting the need for better financial support and policy strategies.

SourceUniversity of Colorado Anschutz Medical Campus·JournalJournal of Cancer Survivorship·DateMay 16, 2025

Epigenetics predicts the aggressiveness of Burkitt Lymphoma, a common pediatric tumor in developing countries

Researchers identified two distinct epigenetic profiles in Burkitt Lymphoma, one associated with a favorable clinical course and the other with early relapse and shorter survival. This discovery has implications for treatment strategies and may lead to personalized medicine approaches.

SourceJosep Carreras Leukaemia Research Institute·JournalBlood Cancer Discovery·TypeExperimental study·DateMay 14, 2025

New research from Mass General Brigham guides treatment regimen for aggressive blood cancer

Researchers at Mass General Brigham found that patients with relapsed/refractory mature T- and NK-cell lymphomas had improved survival rates when treated with small molecule inhibitors as second-line therapy, followed by epigenetic modifiers as third-line therapy. The study, published in the British Journal of Haematolog, also showed t...

SourceMass General Brigham·JournalBritish Journal of Haematology·TypeObservational study·DateMay 1, 2025

Scientists develop super strong antibodies for new cancer treatment

Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.

SourceUniversity of Southampton·JournalNature Communications·TypeExperimental study·DateMay 1, 2025

Genomic analysis provides insight into underpinnings of new treatment combination for deadly, Asian-prevalent lymphoma

A new combination therapy using cemiplimab and isatuximab has shown promising results in a phase 2 clinical trial for extranodal NK/T-cell lymphoma, with 51% of patients achieving complete response. The study validated genomic biomarkers and a prognostic model developed by the National Cancer Centre Singapore, offering potential for mo...

SourceSingHealth·JournalBlood·TypeRandomized controlled/clinical trial·DateApr 16, 2025

Cutting-edge optical genome mapping technology shows promise for diagnosis, prognosis, and therapeutic options of multiple myeloma

Researchers have developed an innovative optical genome mapping technique that can identify structural variants and copy number variations across the entire genome in a single test. The method has been shown to reduce material requirements and improve prognostic stratification for patients with multiple myeloma.

SourceElsevier·JournalJournal of Molecular Diagnostics·TypeExperimental study·DateApr 14, 2025

Blood cancer patients taking Bruton Tyrosine Kinase inhibitors should continue treatment at the time of COVID-19 vaccination, study shows

A new study suggests that blood cancer patients receiving Bruton Tyrosine Kinase inhibitors should continue their therapy while getting vaccinated against COVID-19. The IMPROVE trial found no improvement in antibody responses when BTKi therapy was paused for three weeks around the time of vaccination.

SourceUniversity of Birmingham·JournalThe Lancet Haematology·TypeRandomized controlled/clinical trial·DateApr 1, 2025

New research finds novel drug target for acute myeloid leukemia, bringing hope for cancer patients

Researchers at UT Health San Antonio have identified a novel drug target for acute myeloid leukemia, which showed significant delays in disease progression and improved survival rates. The protein paraspeckle component 1 (PSPC1) plays a crucial role in the disease, and targeting it may offer new treatment options for AML patients.

A new CAR-T-cell therapy tricks cancer cells with a decoy to increase treatment efficiency in B-cell Acute Lymphoblastic Leukaemia

Researchers have developed a TIM-3 decoy that improves the effectiveness of CAR-T cell therapy in treating B-cell Acute Lymphoblastic Leukemia. The decoy blocks the interaction between the tumor and immune cells, allowing CAR-T cells to persist and attack cancer cells more effectively.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalBlood·TypeExperimental study·DateMar 24, 2025

New combination treatment strategy dramatically increases cell death in leukemia

Researchers at VCU Massey Comprehensive Cancer Center have identified an innovative combination treatment strategy that collaborates to kill AML cells. The new approach targets the SRC gene and MCL-1 protein, leading to increased cell death in leukemia cells. This discovery offers a promising new direction for leukemia treatment.

SourceVirginia Commonwealth University·JournalSignal Transduction and Targeted Therapy·TypeMeta-analysis·DateFeb 27, 2025

New guidelines for managing blood cancers in pregnancy

The new guidelines aim to reduce trauma and delays in cancer diagnosis and treatment during pregnancy. Led by Dr Georgia Mills and Dr Gisele Kidson-Gerber, the guidelines provide a practical guide for doctors, including recommendations for diagnosis, staging, imaging safety, therapy, and supportive care.

SourceMacquarie University·JournalThe Lancet Haematology·TypeCommentary/editorial·DateJan 3, 2025

Children’s Hospital Colorado research transforms the standard of care for childhood cancer

The new therapy significantly improves three-year disease-free survival for children with B-ALL, with 96% being disease-free for at least three years. Blinatumomab is now being used in most patients due to its practice-changing breakthrough, offering improved quality of life and reduced side effects.

SourceChildren's Hospital Colorado·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateDec 18, 2024

Autologous stem cell transplants do not improve survival for mantle cell lymphoma patients with undetectable MRD, clinical trial shows

A phase 3 trial shows that autologous stem cell transplants do not improve survival for mantle cell lymphoma patients in complete remission and undetectable minimal residual disease. Patients who remain MRD-positive after induction may benefit from ASCT, but longer follow-up is needed to confirm these findings.

SourceECOG-ACRIN Cancer Research Group·TypeRandomized controlled/clinical trial·DateDec 10, 2024